-transparent.png){kind=logo}
Twenty patients with systemic scleroderma (SSD) and Raynaud's syndrome (RS) received 30-80 mg of corinfar, a blocker of calcium channels, during 14 days. Seventeen patients responded to the treatment. The clinical effect was manifested by a decrease in the rate, duration and intensity of RS attacks. Side effects were recorded in 6 patients, but the drug was discontinued only in 2 patients because of the allergic reactions. During treatment, the patients showed an increase in tissue blood flow parameters. Corinfar may be regarded a drug of choice in the treatment of marked RS in SSD.
Related Publications
A B Shcherbakov, and
N G Guseva, and
E S Mach
February 1985,
Gastroenterologie clinique et biologique,
A B Shcherbakov, and
N G Guseva, and
E S Mach
January 1965,
Bulletin de la Societe francaise de dermatologie et de syphiligraphie,
A B Shcherbakov, and
N G Guseva, and
E S Mach
May 1975,
La Revue du praticien,
A B Shcherbakov, and
N G Guseva, and
E S Mach
September 1957,
Polski tygodnik lekarski,
A B Shcherbakov, and
N G Guseva, and
E S Mach
January 1951,
Casopis lekaru ceskych,
A B Shcherbakov, and
N G Guseva, and
E S Mach
February 1958,
The British journal of dermatology,
A B Shcherbakov, and
N G Guseva, and
E S Mach
February 1985,
Gastroenterologie clinique et biologique,
A B Shcherbakov, and
N G Guseva, and
E S Mach
October 1957,
Polski tygodnik lekarski,
A B Shcherbakov, and
N G Guseva, and
E S Mach
January 1967,
Bulletin de la Societe francaise de dermatologie et de syphiligraphie,
A B Shcherbakov, and
N G Guseva, and
E S Mach
January 1971,
Reumatismo,
